Elicio Therapeutics, Inc.
ELTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001601485
No open-market purchases or sales by Elicio Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $15.3M in total; no superinvestor holds it.
13F holders, Q2 2024
Institutional positions in Elicio Therapeutics, Inc. as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- +2 vs. Q1 2024
- Shares held
- 648.7K
- +242.3K (+59.6%) vs. Q1 2024
- Total value
- $2.68M
- −$400.4K (−13.0%) vs. Q1 2024
- New holders
- 5
- 8 more added
- Sold out
- 3
- 1 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 48 | $15.3M |
| Q1 2026 | 47 | $28.2M |
| Q4 2025 | 37 | $16.6M |
| Q3 2025 | 28 | $20.9M |
| Q2 2025 | 21 | $11.2M |
| Q1 2025 | 24 | $9.80M |
| Q4 2024 | 17 | $2.25M |
| Q3 2024 | 18 | $2.48M |
| Q2 2024 | 20 | $2.68M |
| Q1 2024 | 18 | $3.08M |
| Q4 2023 | 18 | $2.78M |
| Q3 2023 | 18 | $2.80M |
| Q2 2023 | 15 | $2.71M |
| Q1 2023 | 28 | $2.56M |
| Q4 2022 | 30 | $3.98M |
| Q3 2022 | 38 | $4.71M |
| Q2 2022 | 43 | $5.90M |
| Q1 2022 | 47 | $13.8M |
| Q4 2021 | 53 | $20.3M |
| Q3 2021 | 47 | $69.3M |
| Q2 2021 | 41 | $66.5M |
| Q1 2021 | 41 | $92.0M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Elicio Therapeutics, Inc.; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 226,297 | $930.1K | 0.00% | +10,611+4.9% | Added |
| Armistice Capital, LLC | 100,000 | $411.0K | 0.01% | +100,000 | New |
| Geode Capital Management, LLC | 71,508 | $293.9K | 0.00% | +23,812+49.9% | Added |
| CM Management, LLC | 50,000 | $205.5K | 0.19% | −25,000−33.3% | Reduced |
| Arena Investors LP | 50,000 | $205.5K | 3.49% | +50,000 | New |
| Hudson Bay Capital Management LP | 48,720 | $200.2K | 0.00% | +48,720 | New |
| State Street Corp | 21,900 | $90.0K | 0.00% | +4,300+24.4% | Added |
| BlackRock Inc. | 18,985 | $78.0K | 0.00% | +18,068+1,970.3% | Added |
| Meyer Handelman Co | 13,899 | $57.1K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 12,500 | $51.4K | 0.00% | 00.0% | Unchanged |
| Warberg Asset Management LLC | 11,801 | $48.5K | 0.01% | +11,801 | New |
| Northern Trust Corp | 11,180 | $46.0K | 0.00% | +11,180 | New |
| CIBC Private Wealth Group, LLC | 7,000 | $42.6K | 0.00% | 00.0% | Unchanged |
| Steward Partners Investment Advisory, LLC | 1,554 | $6.39K | 0.00% | 00.0% | Unchanged |
| National Bank of Canada | 1,500 | $5.57K | 0.00% | +800+114.3% | Added |
| Bank of America Corp | 1,202 | $4.94K | 0.00% | +56+4.9% | Added |
| Citigroup Inc | 374 | $1.54K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 230 | $945 | 0.00% | +100+76.9% | Added |
| UBS Group AG | 17 | $70 | 0.00% | +1+6.3% | Added |
| Avion Wealth | 78 | $0 | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −11,761−100.0% | Sold out |
| Northwest Capital Management Inc | 0 | $0 | 0.00% | −350−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −50−100.0% | Sold out |